Selinexor in Advanced, Metastatic Dedifferentiated Liposarcoma: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial.

J Clin Oncol · 2022 · PMC9467680 · PMID 35394800

Europe PMC DOI

hedged sentence

0.0600

closest p · 1.2× alpha

0.0600

boldest claim

The sentences

showed a trendP = .06so close (0.05 < p ≤ 0.1)

In addition, as compared with the patients on placebo who did not cross over, those randomly assigned to selinexor showed a trend toward improved OS ( P = .06).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.